HDAC inhibitors for the treatment of cutaneous T-cell lymphomas (Q37993586)

26 August 2017

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas (English)

1 reference

26 August 2017

Sophia Rangwala

1

1 reference

26 August 2017

Chunlei Zhang

series ordinal

2

1 reference

26 August 2017

Madeleine Duvic

series ordinal

3

1 reference

26 August 2017

language of work or name

1 reference

1 March 2012

1 reference

Future Medicinal Chemistry

26 August 2017

1 reference

26 August 2017

4

1 reference

26 August 2017

471-486

1 reference

26 August 2017

4

1 reference

Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002.

26 August 2017

1 reference

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

21 January 2018

1 reference

Mycosis fungoides: pathophysiology and emerging therapies

21 January 2018

1 reference

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

21 January 2018

1 reference

Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome

21 January 2018

1 reference

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma

21 January 2018

1 reference

Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.

21 January 2018

1 reference

Mycosis fungoides in relation to environmental exposures and immune response: a case-control study

21 January 2018

1 reference

Infectious agents in cutaneous T-cell lymphoma

21 January 2018

1 reference

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Role of histone deacetylases and their inhibitors in cancer biology and treatment.

21 January 2018

1 reference

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

21 January 2018

1 reference

Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma

21 January 2018

1 reference

HDAC expression and clinical prognosis in human malignancies

21 January 2018

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

Lysine acetylation targets protein complexes and co-regulates major cellular functions

21 January 2018

1 reference

Histone deacetylase inhibitors: overview and perspectives

21 January 2018

1 reference

Targeting histone deacetyalses in the treatment of B- and T-cell malignancies

21 January 2018

1 reference

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

21 January 2018

1 reference

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization

21 January 2018

1 reference

The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy

21 January 2018

1 reference

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

21 January 2018

1 reference

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

21 January 2018

1 reference

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

21 January 2018

1 reference

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

21 January 2018

1 reference

Function of histone deacetylase inhibitors in inflammation.

21 January 2018

1 reference

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

21 January 2018

1 reference

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

Mitochondria and cell death: outer membrane permeabilization and beyond

21 January 2018

1 reference

Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.

21 January 2018

1 reference

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma

21 January 2018

1 reference

The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

21 January 2018

1 reference

Molecular mechanisms and therapeutic development of angiogenesis inhibitors

21 January 2018

1 reference

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma

21 January 2018

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).

21 January 2018

1 reference

Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death

21 January 2018

1 reference

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

21 January 2018

1 reference

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism.

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma

21 January 2018

1 reference

Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients

21 January 2018

1 reference

Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate

21 January 2018

1 reference

A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.

21 January 2018

1 reference

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

21 January 2018

1 reference

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

21 January 2018

1 reference

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.12.6

1 reference

26 August 2017

1 reference